The Green Organic Dutchman Holdings Ltd.’s (“TGOD”) (TSX:TGOD) is pleased to announce it has entered into a strategic partnership with Epican Medicinals Ltd. This partnership will add an additional 14,000 kgs, taking TGOD’s total organic funded capacity to 130,000 kgs. Epican is a vertically integrated Jamaican cannabis company with cultivation, extraction, manufacturing and retail distribution licenses. This strategic partnership introduces TGOD’s premier organic cannabis brand to the international medical market.

“This represents the first of many strategic partnerships TGOD intends to execute in the coming months,” said Robert Anderson, CEO. “Our value-added approach taken in this investment will set an international M&A framework for capital investment, transfer of knowledge, and sector expertise. We will continue to evaluate international opportunities that will assist us in executing our business plan to become the world’s largest organic cannabis brand,” continued Anderson.


Epican produces high quality cannabis at its primary Blue Mountain cultivation site and has partnered with TGOD to construct a second 125,000 sq. ft. GMP compliant facility. Upon receiving the second site license, both facilities will cultivate high premium organic strains for the Jamaican and international markets. The Company will be working with Eco-Cert to achieve organic certification in Jamaica.

Epican’s extraction laboratory has been designed, licensed and built to GMP standards, establishing the company as a leader in sustainability with Jamaica’s Cannabis Licensing Authority (“CLA”). The company intends to sell a wide range of products such as dried flower, oils, pre-rolled joints, vapes, tinctures, among others. Epican’s initial offering of 11 scientifically formulated products will allow the company to service medical cannabis patients through its network of retail dispensaries (“Herb Houses”).

Jamaican dispensaries, known as Herb Houses, are crucial to the distribution of cannabis in Jamaica. Epican, with its first mover advantage, is opening its flagship dispensary in July 2018 located in Kingston, Jamaica. This will represent the first of many Herb Houses, with several more to be completed by the end of 2018 including locations along Jamaica’s northern coast. These locations will serve the medical needs of Jamaica’s 3 million residents and approximate 3.5 million visitors each year.

Jamaica has long been recognized as a premier location for cannabis enthusiasts and Epican has deep roots in the country. Founders, the McKenzie brothers, have been at the forefront of the nation’s burgeoning medical cannabis industry, including extensive advocacy for the responsible development of the industry. Epican’s social commitment to Jamaica’s agricultural community includes a partnership plan to support Jamaica’s Small Farmer Program. Epican was awarded the country’s historic first cultivation license.

International expansion is an integral part of TGOD’s business plan. The partnership with Epican will provide a low-cost platform from which TGOD is supplied premium Jamaican grown medical cannabis for export to select international jurisdictions, as regulations permit.

TGOD’s partnerships are more than an investment for a portfolio company. TGOD investments are structured as true partnerships, where portfolio companies receive countless hours of support and industry leading knowledge. This knowledge transfer includes cultivation methodology, extraction, R&D, and organic certification, through to accounting, auditing, sales, marketing, and distribution. This is exemplified in TGOD’s investment into Epican and Jamaica, by providing expertise to expedite Epican’s organic certification process through Eco-Cert, developing and refining its sales, marketing, and branding plans, outreach to all-inclusive resorts, and digital marketing focused on medical tourism.

Karibe McKenize, CEO of Epican, stated “We are excited to partner with and benefit from TGOD’s immense knowledge in organic cannabis cultivation. This expertise supports and enhances our authentic Jamaican production and ensures patients receive a product that is completely free from chemical pesticides and synthetic fertilizers. Our partnership with TGOD solidifies our commitment to producing cannabis in the most sustainable and natural methods possible, honouring Jamaica’s historic relationship with the natural and medicinal benefits of the plant.”

In conjunction with the Strategic Partnership Agreement, TGOD has entered into a binding agreement to invest into Epican for a 49.18% interest. Furthermore, TGOD will provide Epican access to its financing facilities to support future expansion requirements. The transaction is subject to customary regulatory and TSX approvals.

“This is the first example of how we can partner with and introduce companies like CBx Technologies and Stillwater Brands to foreign jurisdictions,” said Csaba Reider, the Company’s President. “Through the development of GMP compliant, state-of-the-art extraction labs, TGOD will begin manufacturing these proven brands in international jurisdictions as regulations permit,” continued Mr. Reider.

On Behalf of the Board of Directors,
The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.

The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$315 million dollars and has over 20,000 shareholders.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the future legalization of recreational cannabis and cannabis-infused products in Canada, statements about future research, development and innovation by the Company, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Click here to connect with The Green Organic Dutchman Holdings Ltd.’s (“TGOD”) (TSX:TGOD) for an Investor Presentation.

Source: globenewswire.ca

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less

Sales to Commence Immediately at The Apothecarium Phillipsburg

 TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that it has received the final permit from the NJ Department of Health (“NJ DOH”) to dispense medical cannabis from its first dispensary in New Jersey . The 3,500 square-foot dispensary, located at 55 South Main Street in downtown Phillipsburg is situated in the historic Phillipsburg National Bank & Trust building and is the first Alternative Treatment Center (“ATC”) in Warren County .

Keep reading... Show less